ML19221B300: Difference between revisions

From kanterella
Jump to navigation Jump to search
(Created page by program invented by StriderTol)
 
(Created page by program invented by StriderTol)
 
(One intermediate revision by the same user not shown)
Line 15: Line 15:


=Text=
=Text=
{{#Wiki_filter:United States of America Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or  
{{#Wiki_filter:EXPORT LICENSE NRC LICENSE NO.: XMAT448 United States of America                                                       Page 1 of 7 Nuclear Regulatory Commission                    NRC DOCKET NO.: 11006349 Washington, D.C. 20555 LICENSE EXPIRES: March 31, 2024 Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.
 
LICENSEE                                      ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
production or utilization facilities listed below, subject to the terms and conditions herein.
Cambridge Isotope Laboratories, Inc.                                                     See following page(s) 50 Fontage Road Andover, MA 01810 Attn: Gary Ionta INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)                               OTHER U.S. PARTY(IES) TO EXPORT See following page(s)                          Cambridge Isotope Laboratories, Inc.
NRC LICENSE NO.:Page 1 of 7 NRC DOCKET NO.:
50 Frontage Road Andover, MA 01810 (supplier/distributors)
LICENSE EXPIRES:March 31, 2024 Nuclear Regulatory CommissionWashington , D.C. 20555 EXPORT LICENSE Cambridge Isotope Laboratories, Inc.
50 Fontage Road Andover, MA 01810 LICENSEE ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
OTHER U.S. PARTY(IES) TO EXPORT Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic EnergyAct of 1954, as amended, and the Energy Reorganization Act of 1974.This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of
 
THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVENAME AND TITLE:
DATE OF ISSUANCE:
APPLICANT'S  
APPLICANT'S  


==REFERENCE:==
==REFERENCE:==
Application Dated 02/22/2019              ULTIMATE DESTINATION: India QUANTITY(IES)                                        DESCRIPTION OF MATERIAL(S) OR FACILITY(IES) 10,000 kilograms            Deuterium in the form of deuterium oxide, deuterium gas, and other compounds.
Neither this license nor any right under this license shall be              THIS LICENSE IS INVALID UNLESS SIGNED BELOW assigned or otherwise transferred in violation of the                            BY AUTHORIZED NRC REPRESENTATIVE provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.                  SIGNATURE:          Peter J. Habighorst Digitally    signed by Peter J. Habighorst Date: 2019.08.07 08:24:21 -04'00' This license is subject to the right of recapture or control        NAME AND TITLE:        Peter J. Habighorst, Acting Deputy Director by Section 108 of the Atomic Energy Act of 1954, as                                        Office of International Programs amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of    DATE OF ISSUANCE:          August 07, 2019 the NRC.
EXPORT LICENSE


Appl Dated ULTIMATE DESTINATION:
XMAT448 Page 2 of 7 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
IndiaDESCRIPTION OF MATERIAL(S) OR FACILITY(IES)
: 1.
Peter J. Habighorst, Acting Deputy Director Office of International Programs EXPORT LICENSE Attn: Gary Ionta QUANTITY(IES)
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
SIGNATURE: 10,000 kilograms See following page(s)
: 2.
See following page(s)
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
Cambridge Isotope Laboratories, Inc.
: 3.
50 Frontage Road Andover, MA 01810 (supplier/distributors)
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
Deuterium in the form of deuterium oxide, deuterium gas, and other compounds.
: 4.
XMAT448 Page 2 of 7 ULTIMATE CONSIGNEE (S) IN FOREIGN COUNTRY (IES):                                     
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 5.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 6.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 7.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 8.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)


1.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 3 of 7 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
: 9.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 10.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 11.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 12.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 13.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 14.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 15.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 16.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)


2.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 4 of 7 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
: 17.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 18.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 19.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 20.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 21.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 22.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 23.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 24.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)


3.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 5 of 7 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
 
: 25.
4.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
: 26.
5.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
: 27.
6.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
: 28.
7.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
: 29.
8.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 3 of 7 ULTIMATE CONSIGNEE (S) IN FOREIGN COUNTRY (IES):                          
: 30.
 
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
9.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
: 31.
 
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
10.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
11.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
12.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
13.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
14.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
15.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
16.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 4 of 7 ULTIMATE CONSIGNEE (S) IN FOREIGN COUNTRY (IES):            
 
17.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
18.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
19.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
20.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
21.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
22.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
23.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
24.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 5 of 7ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):                        
 
25.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
26.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
27.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
28.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
29.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
30.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
 
31.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 6 of 7INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): 1.2.3.4.5.6.7.                         


XMAT448 Page 6 of 7 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
: 1.
(for distribution to ultimate consignees)
: 2.
(for distribution to ultimate consignees)
: 3.
(for distribution to ultimate consignees)
: 4.
(for distribution to ultimate consignees)
: 5.
(for distribution to ultimate consignees)
: 6.
(for distribution to ultimate consignees)
: 7.
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)


XMAT448 Page 7 of 7 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
: 8.
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
 
: 9.
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
 
: 10.
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
 
: 11.
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
 
: 12.
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
 
: 13.
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
XMAT448 Page 7 of 7 INTERMEDIATE CONSIGNEE (S) IN FOREIGN COUNTRY (IES):                                      
: 14.
 
(for distribution to ultimate consignees)}}
8.(for distribution to ultimate consignees)
 
9.(for distribution to ultimate consignees)
 
10.(for distribution to ultimate consignees)
 
11.(for distribution to ultimate consignees)
 
12.(for distribution to ultimate consignees)
 
13.(for distribution to ultimate consignees)
 
14.(for distribution to ultimate consignees)}}

Latest revision as of 03:19, 2 February 2020

Export License Issued to Cambridge Isotope Laboratories, Inc. XMAT448, Dated 8/7/19
ML19221B300
Person / Time
Site: 11006349
Issue date: 08/07/2019
From: Peter Habighorst
NRC/OIP
To: Ionta G
Cambridge Isotope Labs
Savoy J
References
Download: ML19221B300 (7)
v • d • e


Text

EXPORT LICENSE NRC LICENSE NO.: XMAT448 United States of America Page 1 of 7 Nuclear Regulatory Commission NRC DOCKET NO.: 11006349 Washington, D.C. 20555 LICENSE EXPIRES: March 31, 2024 Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

LICENSEE ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)

Cambridge Isotope Laboratories, Inc. See following page(s) 50 Fontage Road Andover, MA 01810 Attn: Gary Ionta INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES) OTHER U.S. PARTY(IES) TO EXPORT See following page(s) Cambridge Isotope Laboratories, Inc.

50 Frontage Road Andover, MA 01810 (supplier/distributors)

APPLICANT'S

REFERENCE:

Application Dated 02/22/2019 ULTIMATE DESTINATION: India QUANTITY(IES) DESCRIPTION OF MATERIAL(S) OR FACILITY(IES) 10,000 kilograms Deuterium in the form of deuterium oxide, deuterium gas, and other compounds.

Neither this license nor any right under this license shall be THIS LICENSE IS INVALID UNLESS SIGNED BELOW assigned or otherwise transferred in violation of the BY AUTHORIZED NRC REPRESENTATIVE provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974. SIGNATURE: Peter J. Habighorst Digitally signed by Peter J. Habighorst Date: 2019.08.07 08:24:21 -04'00' This license is subject to the right of recapture or control NAME AND TITLE: Peter J. Habighorst, Acting Deputy Director by Section 108 of the Atomic Energy Act of 1954, as Office of International Programs amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of DATE OF ISSUANCE: August 07, 2019 the NRC.

EXPORT LICENSE

XMAT448 Page 2 of 7 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

2.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

3.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

4.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

5.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

6.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

7.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

8.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448 Page 3 of 7 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

9.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

10.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

11.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

12.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

13.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

14.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

15.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

16.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448 Page 4 of 7 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

17.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

18.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

19.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

20.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

21.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

22.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

23.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

24.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448 Page 5 of 7 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

25.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

26.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

27.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

28.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

29.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

30.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

31.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448 Page 6 of 7 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1.

(for distribution to ultimate consignees)

2.

(for distribution to ultimate consignees)

3.

(for distribution to ultimate consignees)

4.

(for distribution to ultimate consignees)

5.

(for distribution to ultimate consignees)

6.

(for distribution to ultimate consignees)

7.

(for distribution to ultimate consignees)

XMAT448 Page 7 of 7 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

8.

(for distribution to ultimate consignees)

9.

(for distribution to ultimate consignees)

10.

(for distribution to ultimate consignees)

11.

(for distribution to ultimate consignees)

12.

(for distribution to ultimate consignees)

13.

(for distribution to ultimate consignees)

14.

(for distribution to ultimate consignees)

Retrieved from "https://kanterella.com/w/index.php?title=ML19221B300&oldid=2389306"